Steering Committee members

The event is shaped by the following industry leaders

  • Stefano Baila, PhD, Director of Operations & Business Development, Holding F.I.S.
  • Dr Dolores Baksh, Innovation Leader, Cell Therapy Technologies, GE Healthcare
  • Dr Oliver Bartelsen, Global Head of Business Development and Industrial Services, Miltenyi Biotec
  • Dr Nina Bauer, Commercial Development, Autologous Therapies, Lonza, Inc
  • David Brindley, DPhil, FRI, FRSA, MEng, Senior Research Fellow in Healthcare Translation, Department of Paediatrics, University of Oxford
  • Loe Cameron, Global Product Manager - Automation Solutions, Pall Life Sciences
  • Professor John Campbell, Associate Director, Research, Development & Innovation, Scottish National Blood Transfusion Service (SNBTS)
  • Michael Covington, Principal CMC Regulatory Policy and Strategy, Juno Therapeutics, Inc
  • Jeremy Cress, Director Of Operations, Fibrocell Science
  • Dr Wilfried Dalemans, Chief Technical Officer, TiGenix
  • Dr Robert Deans, CTO, BlueRock Therapeutics
  • Janet Downie, Chief Executive Officer, Roslin Cell Therapies
  • Professor Miguel Forte, CEO, Zelluna Immunotherapy; Chief Commercialisation Officer and Chair of Commercialisation Committee, ISCT
  • Richard Grant, Chief Product Officer, FloDesign Sonics
  • Pierre Heimendinger, PharmD, Head of Industrial Development, TxCell
  • Dr Bo Kara, Head Process Development, Cell & Gene Therapy Platform CMC, GlaxoSmithKline
  • Dr Ohad Karnieli, CEO & Co-Founder, ATVIO Biotechnology
  • Mak Khan, PhD, Business Development & Transactions Manager, Cell and Gene Therapy Catapult
  • David Kneen, Vice President, Cell Therapy, Invetech
  • Alexandre Lennaertz, Development Manager, MaSTherCell
  • Dr Stuart Macnab, Principal Scientist, Novartis
  • Anne Plant, PhD, Chief of the Biosystems and Biomaterials Division, National Institute of Standards and Technology (NIST)
  • Ian M. Pope, MBA, PhD, Global Head Cryo Automation, Brooks Life Science Systems
  • Dr Qasim Rafiq, Associate Professor, Cell & Gene Therapy Bioprocessing, Department of  Biochemical Engineering, University College London
  • Maria del Pilar Redondo, MSC, Senior Technical Operations Director, TiGenix
  • Rodney Rietze, PhD, Bioprocess Innovation & Enabling Technologies, Immuno-Oncology, Novartis Institutes for Biomedical Research
  • Dr Isabelle Riviere, Director, Michael G. Harris Cell Therapy & Cell Engineering Facility, Memorial Sloan Kettering Cancer Center
  • Eric Roos, Strategic Alliances Leader, Cell Therapy, Thermo Fisher Scientific
  • Dr Krish Roy, Director, Marcus Center for Therapeutic Cell Characterization and Manufacturing (MC3M), Georgia Tech
  • Dr Greg Russotti, Vice President, Technical Operations, Celgene Cellular Therapeutics
  • Samantha Sbardella, Head of Strategy & Portfolio Development for Cell & Gene Therapy Manufacturing Products & Services, MilliporeSigma
  • Dave Smith, Vice President Global Business Development, Lonza
  • Dr Cenk Sumen, Manager, Technology & Business Development, Hitachi Chemical Advanced Therapeutics Solutions
  • Rafael Tapia, PhD, Head, Manufacturing Facility, Cells for Cells
  • Dr Stephen Ward, Chief Operating Officer, Cell and Gene Therapy Catapult